Top Big Cap Negative News Movers Premarket:  AVBP: -59% Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC SYRE: -2% Pricing of $350.0 Million Public Offering of Common Stock PCVX: -2% Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes 06-OCT-2026 09:13 AM ET